Printer Friendly

NEORX DEMONSTRATES EFFICACY IN ANIMALS OF TWO THERAPEUTIC PRODUCT LINES

 SEATTLE, Feb. 23 /PRNewswire/ -- At the company's annual meeting of shareholders, NeoRx Corporation (NASDAQ: NERX) announced it has demonstrated complete tumor regressions and apparent cures of chemotherapy-resistant human tumors in nude mice. This is the first known demonstration of a small molecule carrier effecting regressions of human tumors.
 "We made significant progress in 1992 on both the scientific and business fronts. Most notably, we secured a partner for worldwide commercialization of our OncoTrac(R) Small Cell Lung Cancer Imaging Kit and ended a dispute with Sterling Winthrop Inc.," said Paul Abrams, M.D., J.D., president and CEO. "We entered 1993 with a lot of positive momentum. This year we will concentrate on furthering our efforts to gain Food and Drug Administration (FDA) product approval for our small cell lung cancer imaging product and moving our therapy products into and through clinical trials."
 Next quarter, NeoRx plans to begin clinical trials of its cancer radioimmunotherapy production incorporating its patented pre-targeting technology. Last summer, NeoRx reported a 300 percent improvement in the therapy ratio in animals (dose to tumor vs. dose in blood).
 Also at the annual meeting, NeoRx announced that it has filed a patent application covering further development of pre-targeting technology. During 1992, the company received 32 U.S. and 12 foreign patents, either issued or allowed. NeoRx now holds 68 U.S. and 25 foreign patents.
 In addition, NeoRx now has both angiographic and pathologic evidence indicating that its approach to preventing restenosis (closure) of arteries following coronary balloon angioplasty is efficacious in a swine animal model.
 NeoRx is progressing as planned to complete all supplemental filings in the U.S. to qualify Boehringer Ingelheim (BI) as the manufacturer of OncoTrac Small Cell Lung Caner Imaging Kit by the third quarter of 1993. "NeoRx and BI have been working excellently together to adhere to this time-frame. NeoRx's Product License Application for this indication has already been reviewed by the FDA and we have received a letter indicating no questions on the clinical utility of the product," said Dr. Abrams.
 BI, the company's European and Japanese marketing licensee and manufacturer for OncoTrac cancer imaging products, has recently indicated its decision not to exercise its option for the OncoTrac Melanoma Cancer Imaging Kit. Dr. Abrams stated, "We have ceased all activities related to OncoTrac Melanoma product approval and are concentrating our resources on our therapy products and our OncoTrac lung cancer imaging products." Abrams indicated that NeoRx may license OncoTrac Melanoma to a third party.
 Dr. Abrams outlined the company's goals for the next 12 months:
 -- To file all supplemental data with the FDA for OncoTrac Small Cell Lung Cancer Imaging Kit
 -- To complete the company's Rhenex(R) phase I conventional radioimmunotherapy cancer trial and to complete the Organon collaboration phase I trial
 -- To begin clinical trials with pre-targeting and prepare for a clinical trial next year with antirestenosis
 -- To complete at least one corporate collaboration involving a major product
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human illnesses with a primary focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA its OncoTrac Small Cell Lung Cancer Imaging Product and has completed a phase III trial for non-small cell lung cancer imaging agent. Targeted biopharmaceuticals to treat cancer and restenosis after angioplasty are in pre-clinical testing.
 -0- 2/23/93
 /CONTACT: Robert M. Littauer, vice president and CFO of NeoRx, 206-286-2519, or Anthony J. Russo, Ph.D., or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX)


CO: NeoRx Corporation ST: Washington IN: MTC SU:

PS-TS -- NY011 -- 9245 02/23/93 08:33 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 23, 1993
Words:610
Previous Article:SCOTTS ANNOUNCES SHARE REPURCHASE
Next Article:HIV-POSITIVE INDIVIDUALS MAY HAVE TROUBLE LOCATING PRIMARY CARE, ACCORDING TO SURVEY OF PHILADELPHIA PHYSICIANS
Topics:


Related Articles
NEORX REPORTS PROMISING EARLY RESULTS IN AVICIDIN CANCER THERAPY STUDIES
A SINGLE DOSE OF NEORX'S AVICIDIN PRODUCES CURES IN PRECLINICAL ANIMAL MODELS
NEORX DRUG SHOWN TO INHIBIT RESTENOSIS IN A SWINE PRECLINICAL MODEL; SCIENTISTS PRESENT TWO STUDIES AT AMERICAN HEART ASSOCIATION CONFERENCE
NEORX'S AVICIDIN ADVANCES IN PHASE I II CANCER THERAPY TRIALS
NEORX COMMENCES BIOSTENT(TM) CLINICAL TRIAL FOR RESTENOSIS; FIRST MOLECULE IN CLINICAL TRIALS TO INHIBIT VASCULAR REMODELING
NeoRx Updates Progress on Verluma(TM), Avidicin(TM) and Biostent(TM)
NeoRx Announces Biostent(TM) Milestone
NeoRx Presents Final Phase I Biostent(R) Data
NeoRx Announces Start of Phase II Avicidin(R) Trials
NeoRx Begins Phase I Lymphoma Trial

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters